Bellerophon Therapeutics Inc’s shares plummeted more than 60 percent on Monday after the company said an injectable heart drug it is developing under license failed in a study. The drug, bioabsorbable cardiac matrix, was licensed from BioLineRx Ltd in 2009 after animal studies showed that it acted as a “scaffold” to support the heart wall and was likely to prevent further structural damage. When BCM is administered after a heart
Two suspected cases of the Middle Eastern Respiratory Virus Syndrome (MERS) have forced a hospital in northern England to shut its emergency department, health officials said on Monday. Two patients at Manchester Royal Infirmary were placed in isolation, but there was no significant risk to others at the hospital or to the general public, Central Manchester University Hospitals Trust said. “Manchester Royal Infirmary Accident and Emergency Department will be closed
In the wake of the movie theater shooting in Lafayette, Louisiana, the question arises: Does media coverage of these tragic events do more harm than good?
In the wake of the movie theater shooting in Lafayette, Louisiana, the question arises: Does media coverage of these tragic events do more harm than good?
By Lisa Rapaport (Reuters Health) – Companies fail to report roughly one in 10 serious and unexpected medication side effects to the U.S. Food and Drug Administration (FDA) within a 15-day window specified by federal regulations to protect patient safety, a study finds. Drug manufacturers are also less likely to disclose serious adverse events within this window when patient deaths are involved than when complications aren’t fatal, according to an
By Lisa Rapaport (Reuters Health) – Companies fail to report roughly one in 10 serious and unexpected medication side effects to the U.S. Food and Drug Administration (FDA) within a 15-day window specified by federal regulations to protect patient safety, a study finds. Drug manufacturers are also less likely to disclose serious adverse events within this window when patient deaths are involved than when complications aren’t fatal, according to an
America, fat and proud of it? Not quite as much anymore.
Allergan CEO Brent Saunders said on Monday the company will use the $36 billion it nets from the sale of its generics business to Teva for more deals, including large, “transformational” merger opportunities. Saunders, who led the $66 billion combination of Actavis and Allergan that closed only a few months ago, told investors that it would use the proceeds from its $40.5 billion sale to Teva to increase the size
America, fat and proud of it? Not quite as much anymore.
Looking for the perfect sport for you? Keep these tips in mind.